Gary Cox
Chairman & Principal
Gary started in the IP profession in 1990 as an Examiner of Patents with the Australian Patent Office (now IP Australia).
In 1991, he moved to Sydney and took up a position with a then leading Sydney based IP firm. In 1994, Gary took up a position with Wrays.
Gary’s practice extends across the following areas in biotechnology and pharmaceuticals:
- advice towards strategic IP development in start-up companies and SME’s;
- drafting patent applications;
- prosecution of patent applications;
- opinion work, including freedom to operate opinions, opinions for regulatory approval of pharmaceuticals as well as general due diligence opinion; and
- contentious matters including:
- Patent oppositions; and
- Litigation – court actions (infringement and revocation actions) in Australia and New Zealand.
Some of the leading contention matters that Gary has been retained to act in:
- Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513 (Acted for Kirin Amgen);
- Pfizer Overseas Pharmaceuticals v Eli Lilly and Co (2005) 225 ALR 416 (Acted for Eli Lilly and Co);
- Genentech, Inc v Ludwig Institute for Cancer Research and Human Genome Sciences, Inc [2006] APO 20 (5 June 2006) (Acted for Human Genome Sciences Inc); and
- Danisco A/S v Novozymes A/S (No 2) [2011] FCA 282 (29 March 2011) (Acted for Danisco A/S)
- Eli Lilly and Company Limited v Apotex Pty Ltd [2013] FCA 214
ly listed Australian biotech company.
Related Sessions
UP
